Leichtkettenerkrankungen im Alter

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Thomas Reiter

Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien


1 Palumbo A. et al.: Personalized therapy in multiple myeloma according to patient age and vulnerability:a report of the European Myeloma Network (EMN). Blood 2011; 118 (17): 4519–4529
2 Rosenberg P.S. et al.: Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood 2015; 125 (2): 410–412
3 Hutchins L.F. et al.: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341 (27): 2061–2067
4 Fried L.P. et al.: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56 (3): M146–156
5 Bieniek J. et al.: Fried frailty phenotype assessment components as applied to geriatric inpatients. Clin Interv Aging 2016; 11: 453–459
6 Magarotto V. et al.: Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 2018; 131 (13): 1495
7 Magarotto V. et al.: Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 2016; 127 (9): 1102–1108
8 Durie B.G.M. et al.: Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant(SWOG S0777):a randomised, open–label, phase 3 trial. Lancet 2017; 389 (10068): 519–527
9 Gavriatopoulou M. et al.: How I treat elderly patients with plasma cell dyscrasias. Aging(Albany NY) 2018; 10 (12): 4248–4268
10 Merz M. et al.: Survival of elderly patients with multiple myeloma – Effect of upfront autologous stem cell transplantation. Eur J Cancer 2016; 62: 1–8
11 Palumbo A. et al.: Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125 (13): 2068–2074
12 Engelhardt M. et al.: A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017; 102 (5): 910–921
13 Buske C. et al.: ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol 2018; 29 (3): 544–562
14 Nuvolone M. et al.: Management of the elderly patient with AL amyloidosis. Eur J Intern Med 2018; 58: 48–56

Neph 03|2020

Herausgeber: Österreichische Gesellschaft für Nephrologie, Prim. Univ.-Prof. Dr. Renate Klauser-Braun, Vorstand der 3. Medizinischen Abteilung, SMZ-Ost – Donauspital, Wien
Publikationsdatum: 2020-09-03